Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials

Simple item page
dc.contributor.authorSayar, Hamid
dc.contributor.authorCripe, Larry D.
dc.contributor.authorSaliba, Antoine N.
dc.contributor.authorAbu Zaid, Mohammad
dc.contributor.authorKonig, Heiko
dc.contributor.authorBoswell, H. Scott
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2019-01-24T19:16:10Z
dc.date.available2019-01-24T19:16:10Z
dc.date.issued2019-02
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationSayar, H., Cripe, L. D., Saliba, A. N., Abu Zaid, M., Konig, H., & Boswell, H. S. (2018). Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials. Leukemia Research, 77, pp 30-33. https://doi.org/10.1016/j.leukres.2018.12.011en_US
dc.identifier.urihttps://hdl.handle.net/1805/18221
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.isversionof10.1016/j.leukres.2018.12.011en_US
dc.relation.journalLeukemia Researchen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectacute myeloid leukemiaen_US
dc.subjectsorafeniben_US
dc.subjectvorinostaten_US
dc.titleCombination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trialsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Sayar_2019_combination.pdf
Size:
449.14 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works